Lanifibranor's NATiV3 Phase 3 readout in MASH will confirm or refute whether pan-PPAR agonism can compete in a market resmetirom now anchors

Bull

A positive outcome would require lanifibranor to achieve the primary composite endpoint (histological improvement in MASH resolution and/or fibrosis reduction) at statistically significant levels, ideally with a magnitude comparable to or exceeding resmetirom's MAESTRO-NASH results. This would validate pan-PPAR agonism as a differentiated mechanism, unlock the Tranche C €55M bond issuance, and position lanifibranor for regulatory submissions in both Western markets and China via the CTTQ partnership.

Bear

The most likely failure mode is missing the primary composite endpoint, as MASH histological trials have high placebo response rates and patient heterogeneity that can dilute treatment effects. Even a partial win — fibrosis improvement without MASH resolution, or vice versa — could be read as insufficient differentiation against resmetirom, and any safety signal tied to the pan-PPAR mechanism (e.g., weight gain, edema, or cardiac concerns historically associated with PPAR-gamma agonism) would be particularly damaging given the competitive bar that has already been set.